Analyzing trends and opportunities in the advanced therapy tool and service provider sectors

Cell & Gene Therapy Insights 2021; 7(10), 1253–1259


Published: 26 October 2021
David Anderson

David Anderson is a General Partner at Ampersand Capital Partners, Boston, MA. David joined Ampersand in 2010 and participates across many sectors in healthcare but with a special focus on CDMOs and biopharma services in the cell and gene therapy arena. David’s current and past board seats include Accuratus, BioClinica, Arranta Bio, Brammer Bio, Elite One Source, Stage Bio, Cellero, Vibalogics, and Genezen. David holds a BSc from the University of Aberdeen, Scotland, a PhD in Cancer Immunology from the University of Sheffield, England and an MBA from Babson College, MA.